Editorial Board — Medscape Infectious Diseases

Board Members

  • Paul A. Offit, MD
    • University of Pennsylvania School of Medicine
      The Children's Hospital of Philadelphia
      Philadelphia, Pennsylvania
  • Jan E. Patterson, MD
    • The University of Texas Health Long School of Medicine at San Antonio
      University Health System
      San Antonio, Texas
  • Robert C. Read, MBChB, MD, FRCP
    • Southampton University Medical School
      Southampton General Hospital
      Southampton, United Kingdom
  • Brad Spellberg, MD
    • Keck School of Medicine at University of Southern California
      Los Angeles County and University of Southern California Medical Center
      Los Angeles, California
 

Board Member Details

Paul G. Auwaerter, MD
Paul G. Auwaerter, MD

Professor of Medicine, John Hopkins University School of Medicine; Clinical Director, Division of Infectious Diseases, Johns Hopkins Hospital, Baltimore, Maryland

Paul G. Auwaerter, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Infectious Diseases Society of America
Received income in an amount equal to or greater than $250 from: Cempra; bioMerieux

Helen W. Boucher, MD
Helen W. Boucher, MD

Professor of Medicine, Division of Geographic Medicine and Infectious Diseases; Director, Infectious Diseases Fellowship Program; Director, Heart Transplant and Ventricular Assist Device Infectious Diseases Program, Tufts University School of Medicine, Boston, Massachusetts

Helen W. Boucher, MD, has disclosed the following relevant financial relationships:
Received research grant from: National Institutes of Health
Received income in an amount equal to or greater than $250 from: Actelion Pharmaceuticals, Ltd; Shire; Merck & Co., Inc.

John Boyce, MD
John Boyce, MD

John Boyce, MD, JM Boyce Consulting, LLC, Middletown, Connecticut

John Boyce, MD, has disclosed the following relevant financial relationships:
Serve(d) as an advisor or consultant for: 3M Company; GOJO Industries; Clorox Company
Plan to serve as consultant to Diversey Care in 2016
Recent (2014-2015) research support from Diversey Care, previously Virox Company

Received income in an amount equal to or greater than $250 from: 3M Company; GOJO Industries; Clorox Company

Matthew E. Falagas, MD, MSc, DSc
Matthew E. Falagas, MD, MSc, DSc

Director, Alfa Institute of Biomedical Sciences, Athens, Greece; Adjunct Associate Professor of Medicine, Tufts University School of Medicine, Boston, Massachusetts

Matthew E. Falagas, MD, MSc, DSc, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Achaogen; AstraZeneca Pharmaceuticals LP; InfectoPharm; Tetraphase Pharmaceuticals; Pfizer Inc
Serve(d) as a speaker or member of a speakers bureau for: Cipla; Merck & Co; sanofi-aventis; Novartis
Received research grant from: Angelini; Rokitan; Astellas Pharma, Inc.; Shionogi

Loren G. Miller, MD, MPH
Loren G. Miller, MD, MPH

Associate Professor of Medicine; Director, Infection Care Program, Department of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California

Loren G. Miller, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Durata Therapeutics
Received research grant from: GlaxoSmithKline; Merck & Co, Inc.; Cerexa; Gilead Sciences, Inc.

Kogieleum K. Naidoo, MB ChB, PhD
Kogieleum K. Naidoo, MB ChB, PhD

Medical Doctor, University of Natal; Head, Treatment Research Programme, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa

Kogieleum K. Naidoo, MB ChB, PhD, has disclosed the following relevant financial relationships:
Serve(d) as executive director for: Board of Control, CAPRISA
Serve(d) as a consultant for: TB in Mines; Wits Health Consortium
Received research grant from: CDC President’s Emergency Plan for AIDS Relief; Newton Fund, South African Medical Research Council; BroadReach Healthcare/USAID; University of Cape Town; Bill & Melinda Gates Foundation; South African Medical Research Council SHIP Program

Paul A. Offit, MD
Paul A. Offit, MD

Professor, Department of Pediatrics, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania; Attending Physician, Department of Pediatrics, Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Paul A. Offit, MD, has disclosed no relevant financial relationships.

Jan E. Patterson, MD
Jan E. Patterson, MD

Professor, Department of Medicine, Division of Infectious Diseases, Associate Dean for Quality & Lifelong Learning, The University of Texas Health Long School of Medicine at San Antonio; Staff Physician, Consultant, Infectious Diseases, University Health System, San Antonio, Texas

Jan E. Patterson, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Pfizer Inc; American Board of Internal Medicine Infectious Disease Board Exam Committee
Received income in an amount greater than or equal to $250 from: Pfizer Inc; American Board of Internal Medicine; Young Living Essential Oils (distributor)

Robert C. Read, MBChB, MD, FRCP
Robert C. Read, MBChB, MD, FRCP

Professor, Infection and Immunity, Southampton University Medical School; Consultant Physician, Southampton General Hospital, Southampton, United Kingdom

Robert C. Read, MBChB, MD, FRCP, has disclosed no relevant financial relationships.

Brad Spellberg, MD

Professor of Clinical Medicine, Keck School of Medicine at University of Southern California; Chief Medical Officer, Los Angeles County and University of Southern California Medical Center, Los Angeles, California

Brad Spellberg, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: BioAIM; Mycomed
Received research grant support from: National Institutes of Health
Have a 5% or greater equity interest in: BioAIM
Received income in an amount equal to or greater than $250 from: Dipexium; Cempra; The Medicines Company; MedImmune; PTC Therapeutics; Tetraphase; AstraZeneca; Merck & Co. Inc; Synthetic Biologics